Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.

Centre of Postgraduate Medical Education

Status: Unknown

Conditions: Hip Osteoarthritis; Blood Loss

Treatments: Drug: dabigatran; Drug: Enoxaparin; Drug: rivaroxaban

Study type: Interventional

Funder types: Other

Identifiers

NCT02085824

CPX-2012

Details and patient eligibility

About

The purpose of this study is to determine which of the following drugs: enoxaparin, dabigatran and rivaroxaban causes least blood loss after total hip replacement (THR).

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• primary, end-stage hip osteoarthritis requiring total hip arthroplasty

Exclusion criteria

• inflammatory arthropathies
• liver disorders
• neoplastic conditions
• clotting disorders

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 3 patient groups

enoxaparin

Experimental group

Description:

enoxaparin 40mg 1x1 s.c. daily, once preoperatively and then daily for 28 days

Treatment:

Drug: Enoxaparin

rivaroxaban

Experimental group

Description:

rivaroxaban 10 mg 1x1 p.o. daily for 28 days after the surgery

Treatment:

Drug: rivaroxaban

dabigatran

Experimental group

Description:

dabigatran 110 mg 1x1 p.o. postoperatively and then 1x2 p.o. for 27 days after the surgery

Treatment:

Drug: dabigatran